Item 8.01. Other Events.
On January 19, 2022, Spero Therapeutics, Inc. (the "Company") announced that the
Biomedical Advanced Research and Development Authority (BARDA), added, and
exercised, a new option on the contract originally awarded to the Company in
2018. The new option increases the total amount of committed funding by
$12.9 million to $46.9 million, increasing the total potential contract value to
$59.7 million. As previously announced, the Defense Threat Reduction Agency
(DTRA) is providing up to approximately $10.0 million, in addition to the total
potential award from BARDA, to cover the cost of the nonclinical biodefense
aspects of the collaboration program for tebipenem HBr. The additional $12.9
million option is expected to provide support for a clinical trial and related
activities for orally administered tebipenem pivoxil's use in treating pediatric
patients with complicated urinary tract infections, including acute
pyelonephritis.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release, dated January 19, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses